The shifting roles and toxicities of cellular therapies in B-cell malignancies

Olivia L. Makos, Christopher R. D'Angelo

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Cellular therapies provide a curative-intent option for patients with relapsedand refractory lymphomas. Current options including high dose chemotherapyfollowed by autologous or allogeneic hematopoietic stem cell transplantation or CD19 chimericantigen receptor T-cell (CART) therapy. The indication varies according to lymphoma sub-type and line oftherapy. The sequencing of these therapies and their use in second-line orlater settings to manage these diseases is undergoing significant changes, withCD19 CAR T becoming a preferred option for relapsed aggressive B-cell lymphoma.The mechanism of both therapies causes significant yet distinctlymphodepletion, infectious, and inflammatory toxicities. The resulting patternand timing of immune reconstitution helps guide risk-mitigating strategies,revaccination, and infectious prophylaxis. In this review, we discuss theindication, efficacy, toxicity and immune reconstitution of autologoushematopoietic stem cell transplantation and CAR T therapy for use in thetreatment of lymphoma.

Original languageEnglish (US)
JournalTransplant Infectious Disease
StateAccepted/In press - 2023


  • autologous hematopoietic stem cell transplantation
  • CAR T-cell therapy
  • cytokine release syndrome
  • immune reconstitution
  • lymphoma

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases


Dive into the research topics of 'The shifting roles and toxicities of cellular therapies in B-cell malignancies'. Together they form a unique fingerprint.

Cite this